Cannabis sector gets high on mergers

The cannabis sector’s urge to merge shows no sign of abating, with Canada’s Canopy Growth Corp agreeing to buy Acreage Holdings, one of the biggest US marijuana growers, in a $3.4bn deal.

The cannabis sector's urge to merge shows no sign of abating. Canada's Canopy Growth Corp., headed by Bruce Linton (pictured), has agreed to buy Acreage Holdings, one of the biggest US marijuana growers, in a $3.4bn deal, notes Kimberly Chin in The Wall Street Journal.

But the tie-up comes with a twist: it depends on cannabis production and sales being legalised by the US federal government. Canopy will pay $300m upfront in cash, with the rest in shares once legalisation occurs. If it doesn't arrive within the next 90 months the deal will automatically be called off. This "non-takeover takeover" is a "smart workaround" for Canopy's shareholders, since it's risking just 2% of its $15bn market capitalisation, says John Foley on Breakingviews.

However, even though Acreage's shareholders receive a 42% premium, the deal "makes less sense" for them because they are "giving up the chance to negotiate a greater premium on a higher share price later". After all, "were cannabis to become federally legal, an established producer might have its pick of suitors".

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

It also means that "Acreage shareholders are effectively taking a bet on Canopy's growth". One hint of what could be in store for the sector when legalisation does take place comes from shares in hemp firms, says Connor Smith in Barron's. Late last year Congress legalised hemp, "opening the floodgates for companies to sell "creams and sprays... said to have a calming effect". With major drugstores such as Walgreens already "on board the hemp hype train", shares in related firms have shot up.

Dr Matthew Partridge

Matthew graduated from the University of Durham in 2004; he then gained an MSc, followed by a PhD at the London School of Economics.

He has previously written for a wide range of publications, including the Guardian and the Economist, and also helped to run a newsletter on terrorism. He has spent time at Lehman Brothers, Citigroup and the consultancy Lombard Street Research.

Matthew is the author of Superinvestors: Lessons from the greatest investors in history, published by Harriman House, which has been translated into several languages. His second book, Investing Explained: The Accessible Guide to Building an Investment Portfolio, is published by Kogan Page.

As senior writer, he writes the shares and politics & economics pages, as well as weekly Blowing It and Great Frauds in History columns He also writes a fortnightly reviews page and trading tips, as well as regular cover stories and multi-page investment focus features.

Follow Matthew on Twitter: @DrMatthewPartri